Navigation Links
Drugs.com Releases Q3 Sales for Top 100 U.S. Drugs: Singulair Drops But Nexium and Abilify Remain the Leading Brands
Date:11/21/2012

NEW YORK, Nov. 21, 2012 /PRNewswire/ -- As in the previous quarter, proton-pump inhibitors, antipsychotics and statins remain in the top-selling therapeutic categories. Merck's asthma and allergy preventive Singulair predictably drops out of the top five drugs due to Q3 patent loss.

Top Five Drugs by Sales, Q3 2012Drug Name

Sales ($000)

% Change (previous
quarter)Nexium

$1,420,907

2.93%Abilify 

$1,405,226

1.89%Crestor

$1,245,527

10.74%Cymbalta

$1,158,353

9.50%Humira

$1,152,261

13.45%AstraZeneca's Nexium, not forecast to lose patent protection until May 2014, once again holds the top spot with over $1.42 billion in sales. Otsuka's leading antipsychotic Abilify continues to run a close race with Nexium, posting sales of $1.40 billion. The antidepressant and pain modifier Cymbalta and the TNF blocker Humira both break their way into the top five and exceed sales of $1.15 billion.

Top Five Sales Gains, Q3 2012

Drug Name

Gain ($000)

% Change (previous
quarter)Humira

$136,622

+13.45%Crestor

$120,825

+10.74%Enbrel

$118,579

+12.51%Cymbalta

$100,533

+9.50%Copaxone

$79,255

+9.93%Humira not only moves into the top five drugs by sales, but also displaces escitalopram to claim the number-one spot for revenue gains with over $136 million. Enbrel, with a doubling of sales gains, is the only other brand besides Humira to reappear in the top five sales gain in Q3 compared to Q2 2012. Crestor, Cymbalta and Copaxone all move into the top five, approaching or exceeding double-digit gains.

Top Five Sales Losses, Q3 2012

Drug Name

Loss ($000)

% Change (previous
quarter)Singulair

-$800,968

-62.20%atorvastatin

-$613,501

-78.25%Lipitor

-$392,788

-67.80%Eloxatin

-$251,500

-55.33%Actos

-$241,058

-41.96%Merck's Singulair drops 20 spots in sales ranking and loses over $800 million in sales due to first-time generic competition. Takeda's Actos, which has been slowly losing sales over the last 12 months, went generic in August and quickly drops 42 percent of revenue.

"Unprecedented pharmaceutical sales losses continue to make headlines in Q3 2012, highlighted by the Singulair patent expiry in August," said Philip Thornton, CEO of Drugs.com. "But these changes can be thought of as a win-win situation -- generic availability enables cost-savings for patients, while loss of exclusivity encourages the pharmaceutical industry to further develop new and life-saving therapeutics."

Pfizer's Lipitor continues to slide and drops 68 spots to close the quarter $392 million in the negative. As expected, the total dollar revenue of Lipitor's generic counterpart atorvastatin rapidly declines, dropping by over $613 million due to the market entrance of multiple generic manufacturers and inevitable price erosion.

Lidoderm, Maxalt and Actoplus Met are the next major brands expected to feel the effect of patent loss before the year's end.

Detailed data on the top 100 drugs can be accessed at:
http://www.drugs.com/stats/top100/sales

About Drugs.com

Drugs.com is the leading online drug information resource with over eight million unique visitors per month (ComScore, October 2012). Providing free, independent, peer-reviewed, and up-to-date information at both consumer and professional levels, Drugs.com empowers patients and caregivers to take charge of their health and be more informed than ever before. The site includes many interactive tools and mobile apps to assist consumers, healthcare professionals and researchers, such as personal medication records, a drug interaction checker, pill identification wizard, symptom checker, pharma sales statistics and more.

For more information, visit: http://www.drugs.com/

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Drugs.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
2. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
3. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
4. ShelfX Releases A Fridge That Knows What You Took
5. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
6. Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System
7. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
8. Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial
9. MD Bioproducts releases HLA-B27 subtype specific antibody.
10. ChemDAQ Releases First Sensor For Detection Of Peracetic Acid In Air
11. Polar Releases H7, a Preeminent Wireless Heart Rate Sensor with Bluetooth Smart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company ... Novartis Pharma AG to distribute NuvoAir,s spirometry technology to physicians ... spirometry platform and Novartis, commitment to address the unmet medical ... ... "We ...
(Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
(Date:9/5/2017)... KEYSTONE, Colo. , Sept. 5, 2017 ... their XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party ... update existing CT scanners and allows compliance with current ... The Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically ... notifications and alerts of potential radiation doses over a ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... After a long health ordeal ... new lease on life with assistance from CreditAssociates. CreditAssociates provides debt relief and ... unsecured debt. The senior is one of the satisfied clients who expressed their ...
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE ... Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, California, who will ... Administration at St. Thomas University in Miami, Florida, was selected from a pool ...
(Date:9/22/2017)... Chicago, IL (PRWEB) , ... September 22, 2017 , ... ... founding attorney Richard L. Pullano has been selected to serve as President ... Association’s 50th President at the Installation and Award Dinner hosted by the NSBA at ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... supplement produced by Native Remedies that helps promote pancreatic health and regulate ... individuals. However, some prescription-based approaches can have negative side effects, and with the ...
(Date:9/22/2017)... ... September 22, 2017 , ... "Success ... the world of Alzheimer’s. Alzheimer’s is a disease estimated to affect the lives ... information published by the Alzheimer’s Association, a leading voice in the fight for ...
Breaking Medicine News(10 mins):